Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Large numbers of hormone replacement therapies (HRTs) are available for the treatment of menopausal symptoms. It is still unclear whether some are more deleterious than others regarding breast cancer risk. The goal of this study was to assess and compare the association between different HRTs and breast cancer risk, using data from the French E3N cohort study. Invasive breast cancer cases were identified through biennial self-administered questionnaires completed from 1990 to 2002. During follow-up (mean duration 8.1 postmenopausal years), 2,354 cases of invasive breast cancer occurred among 80,377 postmenopausal women. Compared with HRT never-use, use of estrogen alone was associated with a significant 1.29-fold increased risk (95% confidence interval 1.02-1.65). The association of estrogen-progestagen combinations with breast cancer risk varied significantly according to the type of progestagen: the relative risk was 1.00 (0.83-1.22) for estrogen-progesterone, 1.16 (0.94-1.43) for estrogen-dydrogesterone, and 1.69 (1.50-1.91) for estrogen combined with other progestagens. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another. This study found no evidence of an association with risk according to the route of estrogen administration (oral or transdermal/percutaneous). These findings suggest that the choice of the progestagen component in combined HRT is of importance regarding breast cancer risk; it could be preferable to use progesterone or dydrogesterone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As mentioned above, although long-term use of progestins is associated with a small increase in the risk of breast cancer, the use of progesterone seems to be free of that risk [16,17].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, current evidence suggests that the use of progesterone with oestrogen is not associated with any long-term increase in breast cancer risk, while the use of progestins carries 16–69% increased risk (depending on the type of progestin) compared with HRT never-use [16,17].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
(1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,458
Self-citationRiboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866 · cited 1×
“E3N is the French component of the European Prospective Investigation into Cancer and Nutrition (EPIC) [17].”
BackgroundSelf-citationEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“(We restricted analysis in this way in our previous study [16], to avoid potential biases described by Ray [25]).”
MethodBreast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Physiological Action of Progesterone in Target Tissues*
Graham, J. D., & Clarke, C. L. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0308 · Cited by 1,008 · cited 1×
“Studies of the effect of progesterone on breast cells have demonstrated that the hormone can exert either growth-promoting, neutral, or antiproliferative effects on the breast tissue [20, 21].”
BackgroundStefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 571 · cited 2×
“3-fold increased breast cancer risk associated with the use of estrogen alone (almost exclusively estradiol compounds, and mostly administered through the skin) differs with that of the WHI estrogen-alone trial which found a decreased risk when oral conjugated equine estrogens were used in a population of older and of…”
Postmenopausal Hormone Therapy and Change in Mammographic Density
Greendale, G. A., Reboussin, B. A., Slone, S., Wasilauskas, C., Pike, M. C., & Ursin, G. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.1.30 · Cited by 419 · cited 1×
“equine estrogens plus cyclic micronized progesterone [26].”
Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel‐Chapelon, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20710 · Cited by 403 · cited 2×
“(We restricted analysis in this way in our previous study [16], to avoid potential biases described by Ray [25]).”
BackgroundMethodSelf-citationAll progestins are not created equal
Stanczyk, F. Z. (2003) · Steroids · doi:10.1016/j.steroids.2003.08.003 · Cited by 226 · cited 2×
“However, small structural changes in progestagens may considerably alter their effects [2,3].”
BackgroundStahlberg, C., Pedersen, A. T., Lynge, E., Andersen, Z. J., Keiding, N., Hundrup, Y. A., Obel, E. B., & Ottesen, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20016 · Cited by 218 · cited 1×
“These results are in line with those of two other European studies [10, 11], which found no difference between the effect of 19-nortestosterone derivatives and medroxyprogesterone acetate (a 17-hydroxyprogesterone derivative with lower androgenic potential than 19-nortestosterone derivatives), implying that other para…”
ResultCarcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment
Cogliano, V., Grosse, Y., Baan, R., Straif, K., Secretan, B., & El Ghissassi, F. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70273-4 · Cited by 186 · cited 1×
“replacement therapy (HRT) has been classified as carcinogenic to humans with respect to breast cancer, on the basis of both observational studies and randomized controlled trials [ 1 ].”
Treatment of menopausal symptoms: what shall we do now?
Hickey, M., Davis, S. R., & Sturdee, D. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66519-1 · Cited by 184 · cited 1×
“Millions of women are still using HRTs, as estrogen remains the most effective treatment to alleviate menopausal symptoms [15].”
BackgroundPostmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb, P. A., Titus-Ernstoff, L. T., Egan, K. M., Trentham‐Dietz, A., Baron, J. A., Storer, B. E., Willett, W. C., & Stampfer, M. J. (2002) · PubMed · Cited by 182
Bakken, K. S., Alsaker, E., Eggen, A. E., & Lund, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20389 · Cited by 144 · cited 1×
“use was associated with a decreased risk of breast cancer in the Women’s Health Initiative (WHI) trial [6], but not in some observational studies [7–14].”
BackgroundAn overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
Lee, S. A., Ross, R. K., & Pike, M. C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602617 · Cited by 117 · cited 2×
“that the excess in risk associated with HRT use diminishes after treatment stop [4, 7, 10].”
BackgroundWood, C. E., Register, T. C., Lees, C. J., Chen, H., Kimrey, S., & Cline, J. M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9276-y · Cited by 96 · cited 1×
“[22] compared the effects of estradiol given with either medroxyprogesterone ace-”
Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study
Ewertz, M., Mellemkjaer, L., Poulsen, A. H., Friis, S., Sørensen, H. T., Pedersen, L., McLaughlin, J. K., & Olsen, J. H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602472 · Cited by 92 · cited 1×
“use was associated with a decreased risk of breast cancer in the Women’s Health Initiative (WHI) trial [6], but not in some observational studies [7–14].”
BackgroundPasqualini, J. R., Paris, J., Sitruk-Ware, R. L., Chetrite, G. S., & Botella, J. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00028-4 · Cited by 83
Postmenopausal hormone therapy and breast cancer risk: The multiethnic cohort
Lee, S. A., Kolonel, L. N., Wilkens, L. R., Wan, P. C., Henderson, B. E., & Pike, M. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21481 · Cited by 65 · cited 1×
“The relationship between estrogen-only therapy and breast cancer risk is also the subject of intense debate: unopposed estrogen use was associated with a decreased risk of breast cancer in the Women’s Health Initiative (WHI) trial [6], but not in some observational studies [7–14].”
Risk of breast cancer with progestins: critical assessment of current data
Santen, R. J. (2003) · Steroids · doi:10.1016/s0039-128x(03)00138-7 · Cited by 59 · cited 1×
“However, the effects of progestagens generally differ according to the experimental conditions, the duration of treatment and the dose concentration [3, 19].”
BackgroundHealthy screened bias in epidemiologic studies of cancer incidence.
Weiss, N. S., & Rossing, M. A. (1996) · PubMed · Cited by 56
Pregnancy, progesterone and progestins in relation to breast cancer risk
Campagnoli, C., Abbà, C., Ambroggio, S., & Peris, C. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.08.015 · Cited by 50 · cited 2×
“The high degree of androgenicity of progestins used in certain HRTs has been hypothesized to play a role in the increased risk of breast cancer [5].”
Muti, P. C., Stanulla, M., Micheli, A., Krogh, V., Freudenheim, J. L., Yang, J., Schünemann, H. J., Trevisan, M., & Berrino, F. (2000) · Cancer Causes & Control · doi:10.1023/a:1008966623901 · Cited by 47 · cited 1×
“However, possible preferential prescribing of the nonandrogenic or antiandrogenic HRTs to women with signs of insulin resistance or hyperandrogenism, who are at higher risk of breast cancer [23], could partly explain our findings.”
ResultSelf-citationEffects of progestogens on the postmenopausal breast
Lignieres, B. D. (2002) · Climacteric · doi:10.1080/713605271 · Cited by 30
Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist
Li, C. I. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.05.015 · Cited by 18 · cited 1×
“In our study, estrogen alone was associated with a significantly lower increase in breast cancer risk than estrogen opposed with a progestagen (with the exception of progesterone or dydrogesterone), in line with the growing evidence that adding certain progestins to estrogen has an adverse impact on breast cancer risk…”
ResultMagnusson (1999) · doi:10.1002/(sici)1097-0215(19990505)81:3<339::aid-ijc5>3.0.co;2-6 · cited 1×
“use was associated with a decreased risk of breast cancer in the Women’s Health Initiative (WHI) trial [6], but not in some observational studies [7–14].”
Background
Cited by
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
“They reported that this risk is lower in estrogen–progesterone or estrogen–dydrogesterone methods than other methods.(74) The result of a case–control study showed that the use of HRT in postmenopausal women and in carriers of BRCA1 mutations does not increase the risk of developing breast cancer.”
Result2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“Role of type of hormone use, dose, and route of administration Some but not all observational data suggest that MP and dydrogesterone may have a lesser association with breast cancer, whereas other synthetic progestogens such as MPA may have a more adverse effect.(268) Randomized trials are needed to confirm these fin…”
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“However, observational data suggest that progesterone or dydrogesterone (5, 89) may be associated with a lower risk, but further studies are required to confirm this.”
BackgroundResult
Metadata
- Authors
- Fournier, A., Berrino, F., & Clavel-Chapelon, F.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- ORCID
- Berrino, Franco
- Venue
- Breast Cancer Research and Treatment
- Published
- 2007-02-27
- Volume
- 107
- Issue
- 1
- Pages
- 103-111
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC2211383
- OpenAlex
- W2051559140
- Cited by
- 693
- References
- 28
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 27 · 2023: 30 · 2022: 37 · 2021: 41 · 2020: 91 · 2019: 43 · 2018: 32 · 2017: 22 · 2016: 24 · 2015: 26 · 2014: 28 · 2013: 41 · 2012: 34
- FWCI
- 30.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- hormone replacement therapy, breast cancer risk, estrogen alone, progestogens, dydrogesterone, progesterone, postmenopausal women, E3N cohort
- MeSH terms
- Adult, Aged, Breast Neoplasms, Dydrogesterone, Estrogens, Female, Humans, Middle Aged, Neoplasm Invasiveness, Progestins, Progesterone, Risk, Cohort Studies, Postmenopause, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.